India specializes in treating Hepatitis C using direct-acting antiviral (DAA) medications. These drugs target the virus directly to achieve cure rates exceeding 95%. Generic medications officially produced in India under license include Sofosbuvir, Daclatasvir, and Velpatasvir. These options treat various genotypes effectively and safely.
- Standard combination: Sofosbuvir and Daclatasvir treat genotypes 1 through 6 efficiently.
- Pan-genotypic coverage: Sofosbuvir plus Velpatasvir serves as a universal treatment option.
- Shortened regimens: Generic Glecaprevir and Pibrentasvir may reduce treatment to 0.5 months.
- Primary specialists: Hepatologists like Dr. Yogesh Batra lead treatment at JCI-accredited facilities.
Bookimed Expert Insight: Indian clinics like Medanta and Artemis Hospitals provide massive capacity for international patients. Our data shows hospitals like Manipal serve 2,000,000 patients annually. This high volume allows doctors to manage complex cirrhosis cases alongside standard antiviral therapy. Patients often choose Delhi or Gurgaon for easier access to large medical networks.
Patient Consensus: Patients emphasize the importance of genotype testing before starting any generic medication. Many note that coordinating pharmacy pickups through hospital translators makes the process much smoother.